California kids and Seniors are going without vision care, and the problem is getting worse

California kids are going without vision care, and the problem is getting worse | KPBS Public Media

Blind Spots: How Broken Insurance Leaves Millions of Americans Without the Vision Care They Need

From schoolchildren misdiagnosed as behavioral problems to seniors who cannot read their medication labels, the gap between what is legally required and what is actually delivered is widening – with consequences for learning, independence, and quality of life. New technology offers partial bridges across this gap, but system reform remains essential.

 

BOTTOM LINE UP FRONT (BLUF): America faces a compounding vision care crisis. Myopia now affects an estimated 36% of U.S. children and is projected to worsen, yet only 16% of Medi-Cal-enrolled California children saw an eye doctor between 2022 and 2024. The coverage system is structurally broken at both ends of the age spectrum: Medicaid mandates eye care for children but provider reimbursement rates are so low that only ~10% of California optometrists accept it; Medicare explicitly excludes routine vision care for the 68 million seniors who depend on it. New federal legislation introduced in 2025 aims to fix the Medicare gap, but the same budget cycle enacted nearly $990 billion in Medicaid cuts, threatening the children's coverage that already exists in law but fails in practice. On a more hopeful note, emerging technologies — adjustable self-refraction spectacles, 3D-printed custom eyewear, and smartphone-based screening tools — offer practical interim bridges between a failed screening referral and formal optometric care, and deserve urgent integration into school-based vision programs.

KEY STATISTICS

36%	Estimated prevalence of myopia among U.S. school-age children
16%	California Medi-Cal children who actually received eye care, 2022-24
68 Million	Medicare beneficiaries with no routine vision coverage
$47	California Medi-Cal reimbursement for a comprehensive eye exam — unchanged for 25 years

I. The Myopia Epidemic: A Growing but Under-Addressed Threat

Nearsightedness is quietly becoming one of the dominant public health challenges of our era. Researchers using 2020 U.S. Census data and Kaiser Permanente Southern California pediatric eye exam records have estimated that approximately 19.5 million American children — a nationwide prevalence of 36.1% — are myopic. Urban children bear the greatest burden at 41%, while rural areas show a rate of around 15.7%. By adolescence, the toll climbs even higher: a large Southern California cohort study found that nearly half of 11- to 13-year-olds were already myopic.

The global trajectory is equally alarming. A February 2025 systematic review and meta-analysis published in the British Journal of Ophthalmology, drawing on data from 1990 through 2023, projects that global myopia incidence will exceed 740 million cases by 2050. The Brien Holden Vision Institute estimated that 50% of the world’s population will be nearsighted by 2050, compared to 23% in 2000. The World Health Organization has separately warned that up to one-fifth of those individuals will face a significantly elevated risk of blindness from complications including glaucoma, cataract, retinal detachment, and myopic macular degeneration.

In the United States, the National Eye Institute projects 44.5 million Americans will be nearsighted in 2050, with steeper increases among African-American and Hispanic populations. Oregon Health & Science University’s Casey Eye Institute notes that the prevailing cause of the rise is behavioral and environmental: the surge in time spent on close-range screens and the steep decline in time outdoors during childhood. Critically, national U.S. prevalence data are now more than 20 years old — predating widespread tablet, smartphone, and laptop use as well as the COVID-19 pandemic’s indoor quarantine period — meaning current estimates almost certainly undercount the true scope.

High myopia — generally defined as a refractive error greater than -6.00 diopters — carries especially serious long-term consequences. A 10-year longitudinal study published in 2025 found that between 2.38% and 3.96% of highly myopic children and adolescents progressed to moderate-to-severe visual impairment over the decade. Early-onset myopia during the school years dramatically increases the probability of reaching high myopia thresholds by adulthood, making childhood the most important window for intervention.

II. The Education Catastrophe Hidden in Blurry Blackboards

The link between uncorrected vision and academic underperformance is well established and clinically significant. An estimated 80% of what a child learns during the first 12 years of life is delivered through visual processing. When refractive errors go uncorrected, the consequences go far beyond squinting at the chalkboard.

A 2024 systematic review published in the Journal of Optometry, examining seven high-quality studies, consistently found that visually impaired students read more slowly than their normally sighted peers, with early intervention offering the most meaningful improvements in educational outcomes. A large Spanish cohort study enrolling more than 10,000 elementary school children found that those with poor academic performance were substantially more likely to have binocular vision disorders (19.98% vs. 7.66%) and abnormal eye motility.

A 2025 study from Shandong Province, China published in Scientific Reports, examining 1,766 primary school children, found that more than half of myopic children were under-corrected. Compared to fully corrected peers, those with undercorrected myopia scored significantly lower in Chinese language, mathematics, and overall average scores. The academic penalty for inadequate vision correction is measurable and statistically robust.

Perhaps the most directly applicable U.S. research comes from Johns Hopkins Wilmer Eye Institute and UCLA, whose independently validated studies of the Vision to Learn school-based glasses program found that children who received glasses gained the equivalent of 2 to 6 additional months of learning per year — with the greatest gains concentrated among students in the bottom quartile of their class. The impact surpassed that of far more costly interventions such as lengthening the school day, providing computers, or creating charter schools.

Yet behavioral misdiagnosis remains a serious systemic problem. Children who cannot see the board or a textbook do not typically report the limitation — they act out, become distracted, appear disengaged, and are misidentified as having behavioral disorders or learning disabilities. In California’s Pomona school district, pediatric optometrist Dr. Ida Chung reports that up to 35% of students fail the school vision screening each year, yet only about 7% of those students then visit an eye doctor and return with glasses. The gap is not a minor administrative inefficiency; it is a structural failure with lifetime consequences for affected children.

 “First and second graders who try on glasses the first time are blown away because they just thought that’s how the world looked.”

— Damian Carroll, Vision to Learn

Vision to Learn: A Mobile Solution Illuminating the Scale of Failure

The nonprofit’s school-based mobile optometry program has found that in the California schools it serves, approximately 70% of children previously prescribed glasses did not own a pair, and another 20% had glasses with outdated prescriptions. In underserved communities nationally, the organization estimates that 95% of children who need glasses do not have them.

III. The Coverage Framework: Strong on Paper, Weak in Practice

Federal law is nominally clear. Under Medicaid’s Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit, children and young adults up to age 21 are entitled to comprehensive vision services — routine eye exams, eyeglasses, contact lenses when medically necessary, and treatment for conditions including amblyopia (lazy eye) and strabismus — at no out-of-pocket cost. These requirements are mandatory and do not vary by state.

But the gap between statutory entitlement and actual care delivery is enormous. In California, a report commissioned by the California Optometric Association based on two years of Medi-Cal data found that just 16% of school-age children on Medi-Cal had a vision-related encounter between 2022 and 2024 — down from 19% eight years earlier. Nearly 47 of California’s 58 counties showed declining rates. Colusa County fell from 20% to just under 2%.

The primary driver of provider non-participation is straightforward: money. California’s Medi-Cal reimbursement rate for a comprehensive eye exam is approximately $47. The California Optometric Association estimates that only about 10% of its members accept Medi-Cal patients. According to Association Executive Director Kristine Shultz, “Our reimbursement rates haven’t increased in 25 years.” In rural counties, even a single optometrist departing from a Medi-Cal panel can eliminate access for thousands of families.

IV. The Medicare Gap: Seniors Left Out Entirely

If the children’s coverage system is broken in practice, the seniors’ coverage system is broken by design. Original Medicare — Parts A and B — explicitly excludes routine eye exams, eyeglasses, and contact lenses for the 68 million Americans age 65 and older who depend on it. If a Medicare beneficiary needs a new eyeglass prescription, Medicare will not pay for the exam.

Limited exceptions exist: Medicare Part B covers annual diabetic retinopathy screenings for individuals with diabetes, annual glaucoma tests for high-risk individuals, and treatment for conditions including age-related macular degeneration and cataracts. Following cataract surgery, Medicare will cover one pair of standard eyeglasses or contact lenses. Medigap supplemental policies do not fill the routine vision gap.

By age 65, approximately one in three Americans has some form of vision-reducing eye disease. Regular exams are not merely cosmetic — they are essential for detecting early-stage conditions when treatment is most effective and for identifying systemic health issues including diabetes and hypertension through the eye. Yet without coverage for routine exams, many seniors forgo care until vision loss is already significant.

Medicare Advantage (Part C) plans commonly include routine vision coverage, but terms, copays, allowances, and provider networks vary substantially. Many seniors, particularly those in rural areas or with limited health literacy, are enrolled in Original Medicare without supplemental coverage. The Prevent Blindness Organization notes that adult vision coverage under Medicaid is optional for states and highly variable — with 12% of Medicaid-enrolled adults in states that provide no routine vision care whatsoever.

V. The Market Structure Behind the Price: How a Single Company Controls Eyewear

The access failures documented in the preceding sections — Medi-Cal children without glasses, seniors paying hundreds of dollars out-of-pocket for a medical necessity — do not exist in an economic vacuum. They are inseparable from the pricing structure of the eyewear industry, which is dominated by a degree of vertical market concentration rarely seen in American consumer goods. Understanding that structure is essential to understanding why coverage gaps have such severe consequences, and why the gap between what glasses actually cost to make and what consumers pay for them is measured not in percentages but in multiples.

A. EssilorLuxottica: The Anatomy of Vertical Integration

The company at the center of the eyewear pricing story is EssilorLuxottica, formed in October 2018 through a $58 billion merger between French ophthalmic lens maker Essilor and Italian frame manufacturer Luxottica. Wikipedia’s entry on the combined entity states plainly: "Essilor and Luxottica were respectively the world’s leading manufacturers of ophthalmic lenses and of eyeglasses; upon the merger, EssilorLuxottica thus became a monopoly." In 2025 the company generated approximately €28.5 billion in revenue and employed more than 200,000 people across 150 countries, serving 300,000 eye care professionals and operating 18,000 stores globally.

The scope of brand ownership is what makes the structure unique. On the frame side, EssilorLuxottica’s proprietary brands include Ray-Ban, Oakley, Oliver Peoples, Persol, Costa Del Mar, Vogue Eyewear, Alain Mikli, and Arnette. It holds eyewear licensing agreements with Ralph Lauren, Giorgio Armani, Prada, Chanel, Versace, Coach, Tiffany & Co., Bulgari, Michael Kors, Burberry, and Dolce & Gabbana — meaning that when a consumer selects a "Chanel" or "Prada" frame at a retail optician, the licensing royalty flows to the same parent company that made the lens and may well own the store. On the retail side, LensCrafters, Sunglass Hut, Pearle Vision, Target Optical, For Eyes, and the online retailers Clearly, Eyebuydirect, and FramesDirect.com are all EssilorLuxottica properties.

The insurance dimension completes the loop. EyeMed Vision Care, the second-largest vision insurance company in the United States, covering approximately 85 million lives as of Q1 2025, is an EssilorLuxottica subsidiary. This means the company simultaneously manufactures the prescription lens, owns the brand on the frame, operates the retail store where the purchase is made, and administers the insurance plan that reimburses part of the cost — while steering the insured patient back to its own network stores to maximize the benefit.

VSP Vision Care, the largest vision insurer in the United States with approximately 80–85 million members, operates a parallel but structurally similar model. VSP owns Marchon Eyewear (acquired for $735 million in 2008, and itself reacquired Italian frame manufacturer Marcolin in December 2025), operates optical labs, owns the Eyeconic online eyewear retailer, and has been expanding its ownership of independent optometry practice assets through its VSP Ventures subsidiary. Together, EyeMed and VSP administer vision benefits for roughly 200 million Americans — accounting for an estimated 85% of the vision benefit manager market — while both companies maintain significant ownership interests in the products those benefits pay for.

 “If that’s not a monopoly, I don’t know what is.”

— E. Dean Butler, founder of LensCrafters, quoted in the In re Eyewear Antitrust Litigation complaint (2024)

B. The Manufacturing Cost Gap

The gap between what eyeglasses cost to manufacture and what consumers pay for them in traditional optical retail is one of the most dramatic in American consumer goods. Basic eyeglass frames typically cost $4–$30 to produce, while designer frames may cost $60–$80 at wholesale. The typical markup at traditional optical retail ranges from 200% to 300%, with the industry average markup on frames approximately 250%. Former LensCrafters executives have described markups of nearly 1,000% on certain products. The cost of a standard plastic acetate frame runs approximately $10 to produce; the average retail price of a pair of frames in the United States is $231.

On the lens side, the margins are equally striking. Anti-reflective coatings, blue-light filters, and progressive lens upgrades cost $15–$25 to add during manufacturing but are sold to consumers for $50–$150 at optical retail — achieving gross margins of 75–85%. Progressive bifocal lenses, which most seniors require, are the highest-margin product category in the traditional optical dispensary. A direct comparison illustrates the scale: a pair of EssilorLuxottica/LensCrafters Ferrari-branded rimless glasses with lenses is priced at approximately $773–$847; a comparable pair from online retailer Firmoo, lenses included, costs $26.99 — a ratio of approximately 29 to 1 for functionally equivalent vision correction.

The online disruption — Zenni, GlassesUSA, Eyebuydirect, and others — is essentially a direct challenge to this markup structure. Zenni prices glasses at manufacturing-cost-plus-modest-margin rather than the traditional 200–300% markup, which is why a basic prescription pair costs $6.95. The existence and growth of these platforms demonstrates that the manufacturing economics support high-quality glasses at a small fraction of traditional retail prices. It also explains why EssilorLuxottica acquired Eyebuydirect and Clearly — bringing the lower-cost online channel back under the same corporate umbrella.

C. The Antitrust Litigation: Filed, Fought, and Dismissed

Consumer antitrust class actions were filed in 2024 under the consolidated case In re Eyewear Antitrust Litigation (U.S. District Court, S.D.N.Y., No. 1:24-cv-04826), alleging that EssilorLuxottica used acquisitions and restrictive agreements to inflate prices for prescription lenses and designer frames. The complaint alleged that "the American consumer eyewear market is fixed" and that the company engaged in "price-fixing schemes for their collective financial gain, deceiving consumers into purchasing eyewear products at supra-competitive prices." The named defendants included EssilorLuxottica's major subsidiaries, EyeMed Vision Care, and a long list of fashion house licensors including Prada, Chanel, Burberry, Kering (Gucci), and others.

On September 26, 2025, U.S. District Judge Mary Kay Vyskocil granted EssilorLuxottica’s motion to dismiss both proposed class actions. The court’s ruling was technical rather than exonerating: it held that the plaintiffs had offered "an implausible and contrived definition" of the relevant product market — a critical threshold issue in antitrust litigation — and had not plausibly demonstrated that EssilorLuxottica possessed sufficient market power to control prices or exclude competition for custom lenses. The judge noted, for example, that the plaintiffs’ own definition of the "Premium Eyewear Market" included Oakley sport sunglasses (an EssilorLuxottica brand) but excluded similarly priced Under Armour sport sunglasses made by competitor Safilo — a distinction that "defies common sense" under antitrust standards. Plaintiffs were given a final opportunity to refile by October 17, 2025.

The company’s defense — that "building a successful company over many decades is not an antitrust violation; it is good business" — reflects a genuine principle of American antitrust law. Vertical integration, aggressive acquisition, and brand licensing are legal business strategies. The legal standard requires demonstrating not just market dominance but specific anticompetitive conduct and consumer harm measured against a properly defined relevant market. When that market includes Costco, Walmart, and a rapidly growing online sector, constructing a watertight legal definition becomes genuinely difficult. The case has not resulted in any finding of liability.

A parallel set of antitrust proceedings has targeted VSP. In 2023, California-based optical chain Total Vision filed suit alleging that VSP used its dominant market position to impose unfair business restrictions and attempted to compel the chain into a below-market buyout. When Total Vision refused, VSP allegedly removed the chain from its provider network. A federal judge denied VSP’s motion to dismiss in February 2024, allowing the case to proceed. The American Optometric Association issued a cease-and-desist letter to VSP in June 2025, citing VSP’s California market dominance and alleging that it was "compelling doctors to accept potentially unfair business practices" by threatening removal from all VSP plans if individual doctors refused to accept fee schedules that, the AOA stated, placed reimbursement at or below the actual cost of providing care. The case was paused for potential settlement in May 2025.

D. The Direct Connection to Children and Seniors Going Without Glasses

The market structure described above is not a separate policy story from the access crisis documented in Sections I through IV of this article. It is a direct and proximate cause of that crisis, operating through at least three identifiable mechanisms.

Mechanism 1 — The Medi-Cal Reimbursement Trap:  California’s $47 reimbursement for a comprehensive eye exam has been frozen for 25 years. That figure did not emerge in a vacuum. Independent optometrists and ophthalmologists who see Medi-Cal patients must still purchase lenses from wholesale labs operating in a market where EssilorLuxottica’s Essilor subsidiary controls an estimated 41% of the prescription lens market in the United States. The cost of practice — rent, staff, equipment, and the wholesale cost of lenses dispensed — has continued rising in a supply chain insulated from competitive pricing pressure. A reimbursement rate that was barely viable in 2000 is catastrophically inadequate against inflated input costs in 2026. The result — only 10% of California optometrists accepting Medi-Cal — means Medi-Cal children cannot find a provider. Their failed school screenings go unaddressed, and they sit in classrooms unable to read the board. The eyewear supply chain sits upstream of that outcome.

Mechanism 2 — The Insurance Loop:  EyeMed and VSP together administer vision benefits for roughly 200 million Americans. When a Medi-Cal managed care plan negotiates vision benefits, it is operating in a market where the two dominant insurers also have financial interests in the products those benefits pay for. An insured patient directed "in-network" is typically directed toward providers dispensing lenses and frames purchased through the same vertically integrated supply chain. Independent optometrists who wish to remain in-network face contracting requirements and fee schedules set by entities that also compete with them at retail. The AOA’s 2025 cease-and-desist to VSP explicitly alleged that "when reimbursement rates are at, or below, the actual cost of providing care, it places doctors in an untenable position" — with the consequence that "a significant number of patients [lose] access to quality vision care."

Mechanism 3 — The Senior Out-of-Pocket Premium:  Seniors on Original Medicare receive no routine vision coverage, so the full retail price of a comprehensive eye exam and prescription glasses falls out-of-pocket. That out-of-pocket price has been inflated by a market structure in which basic frames costing $8–$30 to produce are routinely priced at $200–$400 at traditional optical retail, and progressive lenses costing $20–$40 to add are billed at $150–$300. A senior who needs progressive bifocals — as most seniors do — and who cannot navigate online ordering faces prices shaped by a supply chain with very limited competition. The irony highlighted by the antitrust plaintiffs is particularly acute for this population: the consumer believes they are choosing among dozens of competing premium brands when in practice most of those brands flow to the same parent company. An optician in a LensCrafters recommending a "Prada" frame is recommending a product whose design, license, and retail markup all benefit the same corporate entity.

E. The FTC’s Response and the Online Escape Valve

The Federal Trade Commission has long recognized the consumer harm embedded in this structure and has used its Eyeglass Rule as the primary regulatory tool to preserve consumer choice. The rule, first enacted in 1978 and most recently tightened in June 2024, requires that any eye care provider give the patient a written copy of their prescription at the conclusion of the exam — at no additional charge, without the patient having to ask, and without the provider being permitted to withhold it to compel purchase from their own dispensary. The 2024 update added a requirement that providers document confirmation that the prescription was actually provided, a tightening aimed at practices that had been circumventing the rule’s spirit while complying with its letter.

The Eyeglass Rule is the legal foundation for the entire online glasses market. Without it, the vertically integrated optical dispensary would have no obligation to release the prescription that enables a patient to shop elsewhere. With it, a patient who pays $80–$100 for an exam at Costco Optical or Warby Parker can take that prescription to Zenni and purchase functional glasses for $6.95. This price arbitrage is real and meaningful: for a low-income family whose child needs glasses, the difference between $350 at LensCrafters and $20 at Zenni is the difference between the child seeing the classroom board and not. For a senior on a fixed income paying out-of-pocket, it is equally significant.

The limits of this escape valve are also real. Seniors with complex progressive prescriptions and high refractive errors face genuine fitting challenges online. Children whose prescriptions change rapidly need professional follow-up that online ordering cannot replace. The populations most harmed by the traditional retail pricing structure — low-income families with Medi-Cal children, seniors without transportation or digital literacy — are precisely the populations least equipped to navigate the online market that circumvents that structure. Market concentration in eyewear pricing, like coverage exclusions in Medicare and Medi-Cal, ultimately extracts its heaviest toll from those with the fewest alternatives.

 

Who Actually Competes with EssilorLuxottica?

The market does include genuine competitors, though none at comparable scale. Safilo Group (Italy) is the second-largest frame manufacturer, with brands including Smith Optics, Carrera, and Hugo Boss eyewear licenses. Marcolin (now VSP-owned) and De Rigo are other European competitors. In U.S. retail, Costco Optical operates outside the EssilorLuxottica ecosystem with its own buying power and consistently offers exams at approximately $80 and glasses well below traditional retail pricing. Walmart Vision Centers and America's Best similarly provide lower-cost alternatives outside the dominant supply chain. Warby Parker, though vertically integrated in its own right, has disrupted the mid-market with frames starting at $95 including lenses — and has expanded to in-store eye exams at $85. None of these competitors, individually or collectively, has approached EssilorLuxottica’s combined control over manufacturing, retail, and insurance in the traditional optical market.

 

Sources for this section: EssilorLuxottica Wikipedia entry; EssilorLuxottica Q2/H1 2025 Results press release; Moody’s Credit Opinion, EssilorLuxottica, September 22, 2025; PitchBook EssilorLuxottica profile (2026); VSP Vision Care Wikipedia entry; Oregon Health Authority Health Care Market Oversight Transaction Report 041, January 2025 (VSP/Eyemart acquisition); In re Eyewear Antitrust Litigation, S.D.N.Y. No. 1:24-cv-04826, Opinion and Order, September 26, 2025; A&O Shearman Lit-Antitrust, October 2025; PYMNTS.com, September 28, 2025; American Optometric Association, ‘The AOA Demands Vision Benefit Managers Cease Anti-Doctor Policies,’ June/July 2025; Optics Town, ‘What’s the Real Profit Margin on Glasses?’ November 2025; Auburn University Harbert College case study, ‘Is One Company to Blame for the High Price of Eyewear?’ (Luxottica); Medium/Gaetan Lion, ‘The Baffling Economics of the Eyewear Business,’ August 2024.

VI. Emerging Technologies: Bridging the Gap Between Screening and Care

One of the most significant — and underappreciated — failures in the school vision care pipeline is the interval between a failed screening and the receipt of corrective lenses. Even when a school nurse flags a child and sends home a referral note, weeks or months may pass before formal optometric care is obtained, if it is obtained at all. Research consistently shows that referral notes are lost in backpacks, appointments are not made, and children continue to struggle in class with uncorrected vision. Several emerging technology categories offer practical interim correction during this gap — and some could transform the screening-to-correction pipeline entirely.

A. Self-Adjustable and Dial-Adjusted Spectacles

This is the most clinically validated category for interim correction. Two optical mechanisms have been developed and extensively studied in both developed and developing countries.

Fluid-filled lenses (AdSpecs, Adaptive Eyecare Ltd, Oxford, UK): The fluid-filled lenses consist of two thin membranes sealed at a circular perimeter and secured by a frame. The optical power of the lens is determined by the curvature of its surfaces, controlled by varying the volume of liquid in the lens via two user-controlled pumps marked in diopters attached to the sides of the frames. The lens is sealed and the adjustment mechanism removed after the desired power is obtained. This design provides spherical correction in the range of -6 to +6 diopters.

Alvarez-principle sliding lenses (U-Specs, FocusSpecs, Adlens): These employ two polycarbonate lens elements that slide over each other in a spectacle frame, causing changes in lens power with a simple dial. No fluid is required. A dial on the spectacles can be adjusted to provide refractive correction in the range of approximately -6 to +3 diopters.

Clinical validation in children is encouraging. A randomized clinical trial of children aged 5-11 at Duke University’s pediatric eye clinic found that self-refraction using adjustable-focus spectacles was noninferior to noncycloplegic autorefraction — the standard used in many school screenings. Visual acuity corrected to 20/25 or better was achieved in 79.5% of patients using self-refraction, compared to 85.7% with noncycloplegic autorefraction. Studies in Chinese school children using AdSpecs found even stronger results: the proportion of urban children with visual acuity of 6/7.5 in the better eye improved from 34.8% with their habitually worn (or absent) correction to 92.4% with self-refraction — a dramatic functional improvement that could be delivered on the day of the school screening.

The critical limitation is that all currently available adjustable-focus spectacle technologies only provide spherical correction — addressing myopia and hyperopia — but not cylindrical correction for astigmatism. This is a meaningful constraint: astigmatism affects a substantial minority of children requiring correction. For the majority without significant astigmatism, however, these devices offer a validated, low-cost path to functional vision correction that can be deployed by a trained paraprofessional without an optometrist present.

The published literature is clear on the benefits: self-adjusted spectacles offer the potential for correction of both distance and near vision, applicability for all ages, the empowerment of lay workers, reduced costs of optical and refraction units in low-resource settings, and a relative reduction in costs for refraction services. Cosmetic acceptability — the frames are currently bulkier than standard children’s eyewear — remains a challenge for adoption in U.S. schools, and ongoing design improvements are addressing this.

B. 3D-Printed Custom Glasses

A breakthrough presented at the 2024 American Academy of Ophthalmology (AAO) annual meeting in Chicago deserves serious attention from school-based vision program administrators. Pediatric ophthalmologist Donny Suh, MD, and engineer James Hermsen developed Omni Glasses — 3D-printed adjustable eyewear originally designed for children with ear and facial abnormalities who cannot wear standard glasses — and then investigated extending their use to underserved children with complex eye conditions in remote areas.

A study in Ensenada, Mexico, showed significant improvement in refractive errors among children with amblyopia or strabismus. The glasses are lightweight, customizable on the fly, and manufacturable for as little as $1 per frame. Both children and parents rated their experience highly, averaging 4.75 out of 5. A separately published design study in Contact Lens and Anterior Eye proposed a one-size-fits-all 3D-printed frame with circular lens mounts that can accommodate any axis of astigmatism — addressing the major limitation of fluid-filled and Alvarez-type self-refraction spectacles, which cannot correct astigmatism.

The practical advantage of 3D-printed frames extends beyond cost. Because frames are printed to specification rather than selected from a fixed inventory, they can be customized to fit children with unusual facial geometries, a historically underserved population. The flexible design allows distribution in rural and urban environments alike, with minimal training required to fit and assemble. The frame cost of approximately $1 means that even the lens cost — which still requires conventional optician grinding for a precise prescription — becomes the dominant expense rather than the frame, representing a meaningful reduction in total cost.

In 2025, Modo Eyewear announced that its Buy a Frame – Help a Child See programme, in partnership with Seva Foundation, had reached two million vision screenings, eye exams, prescription glasses, and corrective treatments provided to children at no cost. The company and foundation have committed to establishing Vision Centres in India and Nepal. While this program uses conventional frames, it illustrates the philanthropic and commercial infrastructure emerging around school-based vision care delivery that 3D-printed frames could complement.

C. Smartphone-Based Screening and Refraction Tools

These tools don’t provide correction directly, but they dramatically improve the quality and efficiency of the first step — identifying who needs glasses, and potentially determining the approximate prescription needed. Modern photoscreeners use infrared illumination and digital imaging, have autorefraction capabilities, and typically include decision-support software. Current devices in this category include the Spot Vision Screener, PlusoptiX, and the GoCheck Kids smartphone-based variant, all of which can be operated by trained school staff rather than eye care professionals.

The Peek Acuity app (an Android-based smartphone visual acuity test) has been validated in multiple school-based programs across Kenya, Pakistan, and Paraguay. In a Pakistan school-based program from January 2022 to September 2024, 151,456 children were screened by trained school health supervisors — 5.7% were referred for follow-up care. The smartphone-based approach is particularly promising for rural settings where specialist eye care professionals may be absent.

A 2025 paper in Frontiers in Bioengineering and Biotechnology described an advanced smartphone-based system using image analysis algorithms to derive not just visual acuity but also pupillary distance, sphere, cylinder, and axis of astigmatism simultaneously, with 85% of measurements within 0.50 diopters of clinical standards. This level of accuracy, if it can be achieved consistently across device types and ages, would be sufficient to guide the fitting of self-refraction spectacles or to generate a near-prescription for expedited grinding of inexpensive glasses.

Companies such as EyeQue have developed small clip-on devices that attach to smartphones and use interactive self-refraction to estimate a refractive error, enabling users to obtain approximate prescription data without an in-person optometrist visit. While the American Academy of Ophthalmology has noted limitations — and these tools are not currently designed or marketed for young children — the underlying technology trajectory points toward increasingly accurate remote refraction that could eventually be adapted for school-based use with appropriate clinical oversight.

D. FDA-Approved Myopia-Slowing Spectacle Lenses (Essilor Stellest)

This category does not bridge the gap to care — it changes the nature of the intervention needed. On September 25, 2025, the FDA officially approved Essilor Stellest lenses as the first spectacle lens specifically designed to manage pediatric myopia progression. Unlike standard glasses that only sharpen vision, these lenses are engineered to influence how the eye develops. Children wearing Stellest lenses showed a 71% slower rate of myopia progression over two years compared to those with traditional single-vision lenses, and eye axial length growth was reduced by 53%.

Vanderbilt Eye Institute is currently enrolling children in an NIH-funded, multi-center trial testing Stellest lenses in combination with atropine eyedrops to determine whether the combination outperforms either treatment alone. The study is funded by the National Eye Institute and conducted by the Pediatric Eye Disease Investigator Group, with study visits, eye drops, and eyeglasses provided to participants at no cost.

The significance for the school-based vision care discussion is this: if myopia-slowing lenses become standard of care, the argument for early identification and early correction becomes even more powerful. A child who goes without glasses for two years while waiting for Medi-Cal follow-up not only suffers academically — that child’s myopia may progress significantly faster than a child who received corrective lenses promptly. The case for interim correction technology therefore extends beyond academic performance to preventing the progression toward high myopia and its associated lifetime risk of blindness.

E. The Remaining Bottleneck: Technology Without System

The honest assessment is that the technology for interim correction already exists and is clinically validated for straightforward myopia and hyperopia without significant astigmatism — the majority of cases among school-age children. What is missing is not the optics but the system: a trained school-based facilitator to guide the self-refraction process, a mechanism to distribute the glasses, and a clear protocol for transitioning children to formal optometric care. The self-adjustable spectacles in particular require at least a trained paraprofessional for guidance in younger children.

Programs like Vision to Learn already deploy exactly this kind of school-based infrastructure, with licensed optometrists arriving by mobile clinic and providing same-day exams and glasses. The logical near-term next step would be integrating self-refraction spectacles as an immediate interim measure within that same framework — allowing children to start seeing clearly on the day they are screened, while the mobile clinic appointment is scheduled. For communities where even mobile clinics face long wait times, this interim correction could represent weeks or months of restored learning.

F. Online Vision Technology for Seniors Over 65: An Honest Guidance

The consumer telehealth prescription renewal market has a hard age ceiling that applies uniformly across all major platforms. Warby Parker’s Virtual Vision Test stops at 65. EyeCareLive’s prescription renewal service explicitly states it is not recommended for patients above the age of 65. Lens.com, Lensabl, and Visibly all cap eligibility at 55. The clinical rationale is consistent and grounded in epidemiology: by age 80, more than half of all Americans either have cataracts or have had surgery to remove them, and glaucoma, macular degeneration, and diabetic retinopathy all become markedly more prevalent with advancing age. An automated app that checks visual acuity cannot detect these conditions, and issuing a new prescription to a patient who may have active but undetected disease is a liability no platform is prepared to accept. This ceiling is unlikely to move.

However, framing this as a gap in access for seniors over 65 misses a critical point: Medicare does cover eye care for the serious eye diseases that drive the age ceiling in the first place. The online platforms refuse seniors precisely because of conditions that Medicare is designed — and legally required — to treat. Understanding what Medicare covers, and navigating it effectively, is therefore the central task for seniors seeking vision care, not finding a workaround to automated prescription apps.

 

What Medicare Part B Actually Covers for Senior Eye Care

Original Medicare Part B covers the following ophthalmology services at 80% of the Medicare-approved amount (patient pays 20% coinsurance after the Part B deductible, which is $257 in 2025):

Cataracts:  Surgery is fully covered, including the intraocular lens implant. One pair of standard eyeglasses or contact lenses following surgery is also covered.

Glaucoma:  Annual screening exam covered for high-risk individuals: those with diabetes, a family history of glaucoma, African-Americans aged 50+, or Hispanics aged 65+.

Diabetic Retinopathy:  Annual dilated eye exam covered for all Medicare beneficiaries with diabetes.

Age-Related Macular Degeneration (AMD):  Diagnostic testing and treatment covered, including injectable anti-VEGF drugs such as Avastin, Lucentis, and Eylea administered in an ophthalmologist’s office under Part B.

Medically Necessary Exams:  Eye exams required to diagnose or monitor a medical condition — such as double vision, sudden vision changes, or injury — are covered under Part B.

Routine refraction (the "which is better, one or two?" test to measure a glasses prescription) and the cost of eyeglasses or contact lenses outside the post-cataract exception remain explicitly excluded from Original Medicare.

 

Practical Guidance for Seniors Over 65 in California

Given the age limits on automated online renewal services, the optimal strategy for seniors over 65 in California combines Medicare’s existing coverage for serious eye disease with out-of-pocket use of low-cost options for routine refraction and glasses. The following framework applies to a California senior on Original Medicare with no Medicare Advantage vision coverage.

Step 1 — Annual Ophthalmology Exam (Medicare-Covered if Medically Indicated):  Seniors with diabetes, glaucoma risk factors, AMD, or any prior eye disease should be under the care of an ophthalmologist for annual or more frequent disease-monitoring exams. These visits are billed to Medicare Part B. At that same visit, ask the ophthalmologist to perform and document a refraction as part of the overall exam. While Medicare will not reimburse the refraction component itself, many ophthalmologists include it at no additional charge when it accompanies a covered disease-monitoring visit. Get the written prescription; the FTC’s Eyeglass Rule requires it be provided to you at no extra fee.

Step 2 — Hybrid Teleoptometry for Routine Refraction (No Age Limit):  The one online model without an age ceiling is hybrid teleoptometry, where the patient visits a physical clinic location, a technician performs pre-testing with diagnostic equipment (autorefraction, retinal imaging, glaucoma screening), and a remote optometrist conducts the exam live via video. This is a comprehensive exam in every clinical sense. DigitalOptometrics powers this model at multiple California locations including Total Vision clinics in Culver City and Novato, among others. Walk-in patients receive a complete exam and prescription in approximately 30 minutes. There is no upper age limit because the clinical safety net of real diagnostic equipment and a live physician is fully intact. Costs are comparable to or less than traditional optometry practices, typically $80–$120, and are payable by HSA/FSA if available.

Step 3 — Online Glasses Ordering (No Age Limit):  Once a valid prescription is in hand from any source, ordering glasses online carries no age restriction whatsoever. Zenni Optical offers prescription eyeglasses starting under $10 for single-vision lenses and progressive (bifocal) lenses starting around $25–$35. GlassesUSA offers a prescription scanner that reads the lenses of your current glasses to confirm or reconstruct the prescription, a useful tool for seniors whose written prescription may have expired. Warby Parker’s home try-on program (five frames shipped to your home for free) is valuable for seniors who want to assess fit and appearance before committing. None of these services are restricted by age.

Step 4 — Medicare Advantage as a Long-Term Strategy:  For seniors who are approaching their Medicare Advantage open enrollment period (October 15 – December 7 each year), comparing plans with routine vision benefits is worthwhile. According to KFF, 99% of Medicare Advantage plans offered in 2025 include routine vision coverage. Typical benefits include one annual routine eye exam and a $100–$300 eyewear allowance. This does not replace ophthalmology care for serious eye diseases (which remains covered under Part B regardless of plan), but it adds coverage for the routine refraction and glasses that Original Medicare excludes. EyeMed’s Eyeconic and VSP’s online store are in-network for many Medicare Advantage plans and allow online ordering using plan benefits.

Step 5 — EyeCareLive for Acute, Non-Prescription Eye Issues (No Age Limit for Video Visits):  While EyeCareLive’s prescription renewal service excludes patients over 65, its live video consultation service for acute eye conditions — pink eye, dry eye, styes, eye allergies, and lid swelling — does not carry the same age restriction. At $59 per visit ($29 introductory rate), this provides same-day access to a board-certified optometrist or ophthalmologist for non-emergency conditions that do not require in-person examination, without waiting weeks for an appointment. The platform explicitly lists senior citizens as eligible for this consultation service, with a recommendation that a caretaker or assistant be available if helpful.

The candid summary is this: the fully home-based automated prescription renewal services are simply not designed for, and will not serve, patients over 65 — and the clinical reasons for this are legitimate, not arbitrary. But the combination of Medicare’s existing coverage for serious eye disease, hybrid teleoptometry for routine refraction, and online glasses ordering creates a functional pathway that can reduce total out-of-pocket vision care costs substantially compared to traditional optician pricing, without sacrificing the clinical safety that older patients require. The key is understanding which parts of eye care Medicare already covers well, and using emerging low-cost options for the parts it does not.

 

Additional sources for this subsection: EyeCareLive FAQ, eyecarelive.com/rx-visit/ (2025); DigitalOptometrics, digitaloptometrics.com (2025); Total Vision Culver City / Novato, totalvisionpacificeyecare.com and drcraigmccurdy.com; KFF, "Medicare Advantage 2025 Spotlight," kff.org; Medicare.gov, "Eye Exams (Routine)" and "Cataract Surgery," medicare.gov; National Council on Aging, "Does Medicare Cover Vision for Seniors?" ncoa.org (April 2026); Americans for Vision Care Innovation, americansforvisioncareinnovation.org; Cannon EyeCare, "Glasses Prescription Updates: 2025 Complete Guide," seattleeyecaredoctor.com.

VII. The Legislative Picture: Proposed Fixes Collide With Budget Cuts

Legislation / Bill

 

H.R. 2045 / Medicare Dental, Vision, and Hearing Benefit Act of 2025  [PENDING]

Rep. Lloyd Doggett (D-TX) & Sen. Bernie Sanders (I-VT). Would expand Original Medicare to cover routine eye exams, eyeglasses, and contact lenses for all 68 million beneficiaries. A 2024 Data for Progress poll found 92% of Americans support this expansion. Introduced March 11, 2025 with 115+ cosponsors.

 

H.R. 2527 / Early Detection of Vision Impairments for Children Act of 2025  [PENDING]

Would authorize $5 million per year, FY 2026-2030, for statewide early vision detection and intervention programs, requiring coordination across Medicaid, CHIP, IDEA, and state educational agencies.

 

California AB (Ahrens) — Vision Benefit Quality Measures  [PENDING]

Assemblymember Patrick Ahrens (D-Cupertino), sponsored by California Optometric Association. Would require California to establish vision benefit quality measures and report performance data publicly, enabling identification of counties with deficient access.

 

H.R. 1 / “One Big Beautiful Bill Act” (P.L. 119-21)  [ENACTED]

Signed into law July 4, 2025. Cut gross federal Medicaid and CHIP spending by $990 billion over 10 years per CBO estimates. The law’s work requirements and eligibility restrictions are projected to increase the uninsured population by 7.5 million by 2034 from Medicaid/CHIP cuts alone. Policy analysts warned that states unable to absorb cost shifts would be forced to cut optional Medicaid benefits — including vision care for adults — and reduce provider payments, further shrinking the pool of providers accepting patients.

The intersection of these legislative developments creates a profound tension. Progressive legislators are attempting to add routine Medicare vision coverage for seniors — a reform with overwhelming bipartisan public support — while the enacted reconciliation law simultaneously cuts nearly $1 trillion from the Medicaid system that, imperfectly and inadequately, delivers vision care to children. Georgetown’s Center for Children and Families notes that the law’s per-capita financing constraints are expected to push states toward eliminating optional benefits and cutting provider payments — the precise mechanisms that have already driven California’s optometric participation rate down to 10%.

VIII. What Would Actually Work: Evidence-Based Paths Forward

Research consistently points toward several interventions that meaningfully close the gap between entitlement and delivery. Mobile school-based optometry programs — such as Vision to Learn’s model, validated by Johns Hopkins and UCLA — eliminate the most common barriers: transportation, scheduling, and parental follow-through. Children receive an exam, prescription, and glasses in a single school-day visit.

Integration of interim correction technology into school-based programs represents the most promising near-term innovation. Self-adjustable spectacles, deployed by trained school staff on the day of a failed vision screening, could restore functional vision for the majority of myopic and hyperopic children while formal optometric appointments are arranged. 3D-printed frames expand this to children with atypical facial geometries and, with appropriate lens pairing, to children with astigmatism. Smartphone-based refraction tools offer a path toward same-day prescription approximation that could enable expedited lens grinding without a full optometrist visit.

Increases in provider reimbursement rates are a necessary — if insufficient — structural fix. California’s $47 exam reimbursement, unchanged for 25 years, is the root cause of provider non-participation. Even modest increases toward market rates would bring more optometrists into the Medi-Cal network, particularly in rural counties where access currently depends on a single provider.

Mandatory public reporting of vision care utilization rates by county and managed care plan — as proposed in California’s Ahrens bill — would create accountability where none currently exists. You cannot manage what you do not measure.

For seniors, the evidence-based solution is straightforward in principle: include routine vision care in Original Medicare. Polling shows near-universal public support across partisan lines. The Medicare Dental, Vision, and Hearing Benefit Act of 2025 would do exactly that. The legislative obstacle is not lack of support — it is cost, and the political willingness to structure a financing mechanism to cover it.

Time, however, is a cost too. Every year that a child with uncorrected myopia sits in a classroom seeing a blurry board is a year of academic development lost. Every year that a senior with an uncorrected refractive error cannot read a prescription bottle or recognize a grandchild’s face is a year of independence and quality of life diminished. The myopia epidemic is accelerating, the coverage mechanisms are eroding, and the children most affected are the ones who can least afford to wait. Emerging technology offers a partial and immediate remedy that demands urgent attention from program designers, school administrators, and policymakers alike.

 

Verified Sources & Formal Citations

1.  KPBS / CalMatters. "California kids are going without vision care, and the problem is getting worse." April 2, 2026. https://www.kpbs.org

2.  Fortin P, et al. "The myopia management opportunity in the United States Census using the 2020 census." ARVO meeting, May 2022. Reported by Healio/OSN. https://www.healio.com/news/ophthalmology/20220502/census-shows-high-prevalence-of-pediatric-myopia-in-us

3.  Liang J, et al. "Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050." British Journal of Ophthalmology, 109(3):362-371, February 24, 2025. doi:10.1136/bjo-2024-325427. https://pubmed.ncbi.nlm.nih.gov/39317432/

4.  National Academies of Sciences, Engineering, and Medicine. "Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease." 2024. doi:10.17226/27734. https://www.nationalacademies.org/read/27734/chapter/5

5.  Oregon Health & Science University, Casey Eye Institute. "Myopia on the rise, especially among children." https://www.ohsu.edu/casey-eye-institute/myopia-rise-especially-among-children

6.  Ten-Year Change in Visual Function and Incidence of Visual Impairment in Highly Myopic Children. PMC11702767, January 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11702767/

7.  Systematic review: "Impact of childhood vision impairment on reading and literacy in education." Journal of Optometry, April-June 2024. PMC10641537. https://pmc.ncbi.nlm.nih.gov/articles/PMC10641537/

8.  Sun W, et al. "Correlation analysis between visual factors and academic performance in Chinese children." Scientific Reports, March 2026. doi:10.1038/s41598-026-46397-x. https://www.nature.com/articles/s41598-026-46397-x

9.  Focusing Philanthropy. "2024-25 Vision to Learn Campaign." https://www.focusingphilanthropy.org/campaign/2024-2025-vision-to-learn-campaign/

10.  CMS. "Vision and Hearing Screening Services for Children and Adolescents." https://www.medicaid.gov

11.  CMS Press Release. "Biden-Harris Administration Releases Historic Guidance on Health Coverage Requirements for Children and Youth Enrolled in Medicaid and CHIP." September 27, 2024. https://www.cms.gov

12.  Prevent Blindness. "Public Health Insurance Programs: Medicaid and CHIP." December 2025. https://preventblindness.org/medicaid-benefits-for-eye-care/

13.  Prevent Blindness. "Medicare (Age 65+) and Your Eyes." December 2025. https://preventblindness.org/medicare-65-and-your-eyes/

14.  National Council on Aging. "Does Medicare Cover Vision for Seniors?" April 1, 2026. https://www.ncoa.org/article/medicare-and-vision-coverage/

15.  Doggett/Sanders Press Release. "Doggett, Sanders Introduce Bills to Expand Medicare to Cover Dental, Vision and Hearing." March 11, 2025. https://doggett.house.gov

16.  Congress.gov. H.R. 2045 — Medicare Dental, Vision, and Hearing Benefit Act of 2025. https://www.congress.gov/bill/119th-congress/house-bill/2045

17.  Congress.gov. H.R. 2527 — Early Detection of Vision Impairments for Children Act of 2025. https://www.congress.gov/bill/119th-congress/house-bill/2527/text

18.  Georgetown Center for Children and Families. "Medicaid, CHIP, and ACA Marketplace Cuts in the Budget Reconciliation Law, Explained." December 19, 2025. https://ccf.georgetown.edu

19.  Center on Budget and Policy Priorities. "2025 Budget Impacts: House Bill Would Cut Assistance for Children." June 6, 2025. https://www.cbpp.org

20.  KFF. "Tracking the Medicaid Provisions in the 2025 Reconciliation Bill." August 2025. https://www.kff.org

21.  AAO. "3D Printed Eyeglasses Help Save Children's Sight in Remote, Underserved Communities." October 2024. https://www.aao.org/newsroom/news-releases/detail/3d-printed-eyeglasses-help-save-childrens-sight

22.  AAO EyeWiki. "Self-refraction with adjustable-focus spectacles may help correct refractive errors." Review of Zhao L et al., JAMA Ophthalmology 2023. https://www.aao.org/education/editors-choice/self-refraction-with-adjustable-focus-spectacles-m

23.  Self-adjustable glasses in the developing world. Clinical Ophthalmology, PMC3933712. Dove Press / PubMed. https://pmc.ncbi.nlm.nih.gov/articles/PMC3933712/

24.  Refractive error correction among urban and rural school children using two self-adjustable spectacles. PMC10083862. https://pmc.ncbi.nlm.nih.gov/articles/PMC10083862/

25.  Novel 3-D printed adjustable glasses to address the global financial burden of pediatric eyeglasses. Contact Lens and Anterior Eye, 2022. doi:10.1016/j.clae.2022.101715. https://www.sciencedirect.com/science/article/abs/pii/S1091853122003512

26.  Latif MZ et al. Pakistan school-based vision screening using Peek tool. BMC Public Health, November 2025. https://link.springer.com/article/10.1186/s12889-025-25112-x

27.  Salmerón-Campillo RM, et al. "Accuracy and precision of a sphero-cylindrical over-refraction app for smartphones." Ophthalmic and Physiological Optics, 2025. Cited in: Frontiers in Bioengineering and Biotechnology, November 2025. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1678800/full

28.  Insight Vision Center Optometry. "A New Era in Myopia Care: FDA Approves Stellest Lenses for Children." October 1, 2025. https://www.insightvisionoc.com

29.  Vanderbilt Health News. "Study seeks to determine best way to treat myopia in children." December 2, 2025. https://news.vumc.org/2025/12/02/study-seeks-to-determine-best-way-to-treat-myopia-in-children/

30.  AMFG.ai. "How 3D Printing is Revolutionising Eyewear." March 28, 2025. https://amfg.ai/2025/03/28/how-3d-printing-is-revolutionising-eyewear